DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

Phase 3

Completed

Conditions: Graft Rejection

Interventions: Drug: mycophenolate mofetil
Drug: everolimus
Drug: cyclosporine
Drug: corticosteroids

First Posted Date: 2006-03-08

Last Posted Date: 2012-08-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 721

Registration Number: NCT00300274

Locations: 🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

and more 61 locations

MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive

Phase 3

Terminated

Conditions: De Novo Kidney Transplant

First Posted Date: 2006-02-01

Last Posted Date: 2011-11-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT00284921

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Phase 3

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Lapatinib (GW572016) oral tablets
Drug: Paclitaxel infusion
Drug: Placebo

First Posted Date: 2006-01-25

Last Posted Date: 2023-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 444

Registration Number: NCT00281658

Locations: 🇺🇦
Novartis Investigative Site, Zaporizhzhia, Ukraine

Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: TKI258

First Posted Date: 2006-01-20

Last Posted Date: 2010-06-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT00279773

Locations: 🇺🇸
The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Phase 3

Terminated

Conditions: Neoplasms, Breast

Interventions: Drug: lapatinib
Drug: paclitaxel
Drug: trastuzumab

First Posted Date: 2006-01-09

Last Posted Date: 2023-04-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 63

Registration Number: NCT00272987

Locations: 🇧🇪
Novartis Investigative Site, Liege, Belgium

Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Patupilone

First Posted Date: 2006-01-09

Last Posted Date: 2017-02-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT00273312

Locations: 🇨🇳
Novartis Investigative Site, Tai Chung Municipality, Taiwan

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants

Phase 3

Completed

Conditions: Pancreas Transplantation
Kidney Transplantation

Interventions: Drug: Enteric-coated mycophenolate sodium (EC-MPS)

First Posted Date: 2005-12-20

Last Posted Date: 2011-05-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT00267150

Locations: 🇩🇪
Universitätsklinikum Charité Campus Virchow Klinikum Berlin Nephrologie und Internistische Intensivmedizin, Berlin, Germany

Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

Phase 4

Completed

Conditions: Osteoarthritis
Controlled Hypertension

First Posted Date: 2005-12-20

Last Posted Date: 2017-02-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1020

Registration Number: NCT00267176

Locations: 🇩🇪
Novartis, Nuernberg, Germany
🇺🇸
Southern Illinois Clinical Research, O'Fallon, Illinois, United States

RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency

Phase 3

Completed

Conditions: Liver Transplantation

Interventions: Drug: Calcineurin inhibitors (CNI)
Drug: Everolimus
Drug: Mycophenolate acid (MPA)/ Azathioprine (AZA)
Drug: Steroids

First Posted Date: 2005-12-20

Last Posted Date: 2011-04-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 145

Registration Number: NCT00267189

Locations: 🇨🇭
Novartis Investigative Site, Basel, Switzerland
🇩🇪
Novartis Investigational Site, Germany, Germany

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Phase 2

Completed

Conditions: Leukemia, Myeloid, Chronic

Interventions: Drug: AMN107

First Posted Date: 2005-12-12

Last Posted Date: 2017-03-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT00264160

Locations: 🇮🇱
Novartis Investigative Site, Tel Hashomer, Israel

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy